A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced Cancer
Interventions: DRUG: Avelumab|DRUG: Utomilumab|DRUG: PF-04518600|DRUG: PD 0360324|DRUG: CMP-001
Sponsor: Pfizer